Biography

Jin leverages his strong scientific background to support clients across a broad range of patent and other intellectual property matters. With a Ph.D. in organic chemistry and prior experience as a pharmaceutical research scientist, he brings a deep understanding of the science underlying his clients’ innovations.

Jin represents clients in proceedings before the Patent Trial and Appeal Board, including inter partes review and post-grant review, as well as in investigations before the International Trade Commission. He also advises clients on the legal aspects of drug discovery and development and on strategies related to abbreviated new drug applications (ANDAs).

He has led numerous intellectual property due diligence investigations for biotechnology and biopharmaceutical companies in connection with multimillion-dollar mergers and acquisitions. His experience includes preparing legal opinions on patent infringement and validity involving small-molecule drug candidates, antibody-drug conjugates (ADCs), small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), polymorphs, formulations, synthetic processes, and treatment regimens. He has also prosecuted patent applications relating to therapeutic compounds, drug formulations, manufacturing processes, and mechanical devices.

As Co-Leader of the firm’s China IP initiative, Jin draws on his in-depth knowledge of discovery research, product development and the intellectual property landscape to assist clients with business and IP interests in both China and the United States.

Patents

  • U.S. Pat. No. 8,735,414, 7,973,069, 7,781,478, 7,772,271, co-inventor with G. Karp, et al.

Jin leverages his strong scientific background to support clients across a broad range of patent and other intellectual property matters. With a Ph.D. in organic chemistry and prior experience as a pharmaceutical research scientist, he brings a deep understanding of the science underlying his clients’ innovations.

Jin represents clients in proceedings before the Patent Trial and Appeal Board, including inter partes review and post-grant review, as well as in investigations before the International Trade Commission. He also advises clients on the legal aspects of drug discovery and development and on strategies related to abbreviated new drug applications (ANDAs).

He has led numerous intellectual property due diligence investigations for biotechnology and biopharmaceutical companies in connection with multimillion-dollar mergers and acquisitions. His experience includes preparing legal opinions on patent infringement and validity involving small-molecule drug candidates, antibody-drug conjugates (ADCs), small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), polymorphs, formulations, synthetic processes, and treatment regimens. He has also prosecuted patent applications relating to therapeutic compounds, drug formulations, manufacturing processes, and mechanical devices.

As Co-Leader of the firm’s China IP initiative, Jin draws on his in-depth knowledge of discovery research, product development and the intellectual property landscape to assist clients with business and IP interests in both China and the United States.

Patents

  • U.S. Pat. No. 8,735,414, 7,973,069, 7,781,478, 7,772,271, co-inventor with G. Karp, et al.

Before Fox Rothschild

Prior to joining Fox Rothschild, Jin worked as a patent attorney at a national law firm, where he advised clients on intellectual property matters and handled a wide range of patent needs, including infringement and validity analyses as well as patent prosecution.

Before entering the legal field, Jin was a research scientist for PTC Therapeutics and Johnson & Johnson Pharmaceutical R&D, LLC, developing and researching high potency drug candidates.

Jin received his Ph.D. in organic chemistry from the University of Maryland at College Park before serving as a postdoctoral associate in the Duke University Department of Chemistry. As a postdoctoral associate, Jin synthesized demethylasterriquinones in the discovery of anti-diabetic agents.

Bar Admissions

  • New Jersey
  • Pennsylvania
  • U.S. Patent & Trademark Office

Education

  • Rutgers Law School (J.D., 2013)
  • University of Maryland, College Park (Ph.D., 1998)
    • Organic Chemistry
  • Nankai University, Tianjin, China (B.S.)
    • Chemistry

Languages

  • Chinese - Mandarin

Honors & Awards

Selected to the “Ones to Watch” list for Intellectual Property Law and Patent Litigation in Princeton, NJ (2026)
This award is conferred by Best Lawyers. A description of the selection methodology is available here. No aspect of this advertisement has been approved by the Supreme Court of New Jersey.